Fidelity Investments’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-2,239,223
Closed -$104M – 5640
2023
Q2
$104M Sell
2,239,223
-3,441,317
-61% -$119M 0.01% 974
2023
Q1
$163M Buy
5,680,540
+483,183
+9% +$14.3M 0.01% 791
2022
Q4
$162M Buy
5,197,357
+1,774,433
+52% +$57.9M 0.02% 766
2022
Q3
$69.4M Buy
3,422,924
+1,512,596
+79% +$27.6M 0.01% 1099
2022
Q2
$29.6M Buy
1,910,328
+1,569,206
+460% +$27M ﹤0.01% 1486
2022
Q1
$6.53M Sell
341,122
-51,478
-13% -$919K ﹤0.01% 2288
2021
Q4
$9.9M Sell
392,600
-571,900
-59% -$16.8M ﹤0.01% 2116
2021
Q3
$31.6M Buy
+964,500
New +$32.8M ﹤0.01% 1627

Fidelity Investments's DICE Position: Q3 2023 in Review

Fidelity Investments sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 2,239,223 shares — an estimated $104M sold.

Fidelity Investments first reported a position in DICE in Q3 2021 and held it in 8 quarters. The position peaked at $163M in Q1 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Fidelity Investments reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Fidelity Investments sold 2,239,223 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $104M.
  • Fidelity Investments first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • Fidelity Investments's DICE Therapeutics, Inc. Common Stock position peaked at $163M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.